OKYO Pharma Granted European Patent Enhancing IP Portfolio With Novel OK-101 Chemerin Analogs
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has been granted a European patent for its novel OK-101 chemerin analogs, enhancing its intellectual property portfolio.
August 06, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OKYO Pharma has been granted a European patent for its novel OK-101 chemerin analogs, which strengthens its intellectual property portfolio.
The granting of a European patent for OK-101 chemerin analogs is a significant milestone for OKYO Pharma, as it enhances the company's intellectual property portfolio. This development is likely to positively impact the company's stock price in the short term due to the strengthened IP position and potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100